04:29 AM EDT, 04/27/2026 (MT Newswires) -- GSK (GSK) unit Tesaro confirmed that the Delaware Chancery Court granted a motion to dismiss filed by AnaptysBio (ANAB) against Tesaro's claim for anticipatory breach, Tesaro said Monday.

Tesaro said the ruling does not address the core contractual dispute or impact its remaining declaratory judgment claim, which it will pursue at trial, while it and GSK maintained that AnaptysBio's allegations lack merit.

AnaptysBio alleged that Tesaro failed to meet obligations under a March 2014 licensing deal and signaled plans to revoke its dostarlimab license, prompting Tesaro to file the lawsuit, it added.